Search Results - "Bergsland, Emily B"

Abstract CT279: DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas by Gambardella, Valentina, Greystoke, Alastair, Reck, Martin, Liu, Meiruo, Mueller, Martha, Duenzinger, Ulrich, Bergsland, Emily B., Owonikoko, Taofeek

“…Abstract Background: Small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC) of the lung, and extrapulmonary NEC (epNEC) are…”
Get full text

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting by Singh, Simron, Hope, Thomas A, Bergsland, Emily B, Bodei, Lisa, Bushnell, David L, Chan, Jennifer A, Chasen, Beth R, Chauhan, Aman, Das, Satya, Dasari, Arvind, Del Rivero, Jaydira, El-Haddad, Ghassan, Goodman, Karyn A, Halperin, Daniel M, Lewis, Mark A, Lindwasser, O Wolf, Myrehaug, Sten, Raj, Nitya P, Reidy-Lagunes, Diane L, Soares, Heloisa P, Strosberg, Jonathan R, Kohn, Elise C, Kunz, Pamela L

“…Abstract Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several…”
Get full text